nach oben

Erschienen in:

06.11.2019 | Overactive Bladder (U Lee and S Adelstein, Section Editors)

Is Vaginal Laser Effective for Overactive Bladder? Results of a Systematic Review

verfasst von: Gloria Calagna, Marianna Maranto, Emanuela Ognibene, Salvatore Polito, Pasquale De Franciscis, Roberta Granese, Gaspare Cucinella

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of this review is to determine the efficacy of laser treatment in overactive bladder (OAB) syndrome in women.

Recent Findings

In international literature, there are few studies focusing on OAB symptoms. The proposed treatments included thulium laser, fractional CO2 laser and Erbium:YAG laser.

Summary

Although the analysed studies are not RCTs, the results show the efficacy of laser treatment in OAB symptoms, also compared to conventional medical and surgical treatments. However, these tests must be implemented with RCTs and with large patient samples.

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20. https://doi.org/10.1002/nau.20798.CrossRefPubMed

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15. https://doi.org/10.1016/j.eururo.2006.09.019.CrossRefPubMed

Steward WF, Van Rooyen JB, CundiffGW AP, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36. https://doi.org/10.1007/s00345-002-0301-4.CrossRef

White N, Iglesia CB. Overactive Bladder. Obstet Gynecol Clin N Am. 2016;43:59–68. https://doi.org/10.1016/j.ogc.2015.10.002.CrossRef

Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6:S580–90.PubMed

Nystrom E, Sjostrom M, Stenlund H, Samuelsson E. ICIQ symptom and quality of life instruments measure clinically relevant improvements in women with stress urinary incontinence. Neurourol Urodyn. 2014;34:747–51. https://doi.org/10.1002/nau.22657.CrossRefPubMed

Thüroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, et al. EAU Guidelines on Urinary Incontinence. Eur Urol. 2011;59:387–400. https://doi.org/10.1016/j.eururo.2010.11.021.CrossRefPubMed

• Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–62. https://doi.org/10.1016/j.eururo.2008.06.047Review and meta-analysis on the main available medical therapy for OAB. CrossRefPubMed

Liang CC, Hsieh WC, Huang L. Outcome of coexistent overactive bladder symptoms in women with urodynamic urinary incontinence following anti-incontinence surgery. Int Urogynecol J. 2016;28:605–11. https://doi.org/10.1007/s00192-016-3153-y.CrossRefPubMed

10.

Athanasiou S, Grigoriadis T, Giannoulis G, Protopapas A, Antsaklis A. Midurethral slings for women with urodynamicmixed incontinence: what to expect? Int Urogynecol J. 2013;24:393–9. https://doi.org/10.1007/s00192-012-1859-z.CrossRefPubMed

11.

Jain P, Jirschele K, Botros SM, Latthe PM. Effectiveness of midurethral slings in mixed urinary incontinence: a systematic review and meta-analysis. Int Urogynecol J. 2011;22:923–32. https://doi.org/10.1007/s00192-011-1406-3.CrossRefPubMed

12.

Lin YH, Hsieh WC, Huang L, Liang CC. Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence. Taiwan J Obstet Gynecol. 2017;56:815–20. https://doi.org/10.1016/j.tjog.2017.10.020.CrossRefPubMed

13.

•• Perino A, Cucinella G, Gugliotta G, Saitta S, Polito S, Adile B, et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results. Eur Rev Med Pharmacol Sci. 2016;20:2491–7 One of the first trials on the application of laser CO ₂for OAB symptoms. PubMed

14.

Ogrinc UB, Senčar S, Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. Lasers Surg Med. 2015;47:689–97. https://doi.org/10.1002/lsm.22416.CrossRefPubMedPubMedCentral

15.

•• Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Falagas ME, Salvatore S, et al. Microablative fractional CO₂ laser for the genitourinary syndrome of menopause: up to 12-month results. Menopause. 2019;26:248–55. https://doi.org/10.1097/GME.0000000000001206This is the most trial on efficacy of laser CO ₂for the genitourinary syndrome of menopause. CrossRefPubMed

16.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Int J Surg. 2010;8:336–41. https://doi.org/10.1016/j.ijsu.2010.02.007.CrossRefPubMed

17.

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.

18.

Okui N. Comparison between erbium-doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence. World J Urol. 2019;37:885–9. https://doi.org/10.1007/s00345-018-2445-x.CrossRefPubMed

19.

•• Okui N. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists. World J Urol. 2019. https://doi.org/10.1007/s00345-019-02644-7This trial compared erbium:YAG laser treatment vs standard medical therapy. CrossRef

20.

Tovar-Huamani J, Mercado-Olivares F, Grandez-Urbina JA, Pichardo-Rodriguez R, Tovar-Huamani M, García-Perdomo H. Efficacy of fractional CO₂ laser in the treatment of genitourinary syndrome of menopause in Latin American Population: First Peruvian experience. Lasers Surg Med. 2019;51:509–15. https://doi.org/10.1002/lsm.23066.CrossRefPubMed

21.

Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas ME, et al. The effect of microablative fractional CO₂ laser on vaginal flora of postmenopausal women. Climacteric. 2016;19:512–8. https://doi.org/10.1080/13697137.2016.1212006.CrossRefPubMed

22.

Pitsouni E, Grigoriadis T, Tsiveleka A, Zacharakis D, Salvatore S, Athanasiou S. Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: an observational study. Maturitas. 2016;94:131-136. https://doi.org/10.1016/j.maturitas.2016.09.012 CrossRef

23.

Pitsouni E, Grigoriadis T, Falagas ME, Salvatore S, Athanasiou S. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017;103:78–88. https://doi.org/10.1016/j.maturitas.2017.06.029.CrossRefPubMed

24.

Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climateric. 2015;18:219–25. https://doi.org/10.3109/13697137.2014.975197.CrossRef

25.

Perino A, Calligaro A, Forlani F, Tiberio C, Cucinella G, Svelato A, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas. 2015;80:296–301. https://doi.org/10.1016/j.maturitas.2014.12.006.CrossRefPubMed

26.

•• Flint R, Cardozo L, Grigoriadis Rantell TA, Pitsouni E, Athanasiou S. Rationale and design for fractional microablative CO₂ laser versus photothermal non-ablative erbium:YAG laser for the management of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial. Climacteric. 2019;22:307–11. https://doi.org/10.1080/13697137.2018This trial compared CO2 laser and erbium:YAG laser for genitourinary syndrome of menopause. CrossRefPubMed

27.

Gaspar A, Maestri S, Silva J, Brandi H, Luque D, Koron N, Vižintin Z. Intraurethral Erbium: YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: A pilot study. Lasers in surgery and medicine. 2018;50:802-807. https://doi.org/10.1002/lsm.22826 CrossRef

28.

Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2016;49:160–16. https://doi.org/10.1002/lsm.22569.CrossRefPubMedPubMedCentral

29.

Drnovsek-Olup B, Beltram M, Pizem J. Repetitive Er:YAG laser irradiation of human skin: A histological evaluation. Lasers Surg Med. 2004;35:146–51. https://doi.org/10.1002/lsm.20080.CrossRefPubMed

30.

Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: Consensus and controversies. Laser Surg Med. 2017;49:137–59. https://doi.org/10.1002/lsm.22637.CrossRef

31.

Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO₂ laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17:363–9. https://doi.org/10.3109/13697137.2014.899347.CrossRefPubMed

32.

• Behnia-Willison F, Sarraf S, Miller J, Mohamadi B, Care AS, Lam A, et al. Safety and long-term efficacy of fractional CO₂ laser treatment in women suffering from genitourinary syndrome of menopause. Eur J Obstet Gynecol Reprod Biol. 2017;213:39–44. https://doi.org/10.1016/j.ejogrb.2017.03.036This trial reported data on long-term efficacy of CO ₂laser for genitourinary syndrome of menopause. CrossRefPubMed

33.

Gaspar A, Addamo G, Brandi H. Vaginal fractional CO₂ laser: a minimally invasive option for vaginal rejuvenation. Am J Cosmet Surg. 2011;28:156–62. https://doi.org/10.1177/074880681102800309.CrossRef

34.

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016:704–11. https://doi.org/10.1016/j.ajog.2016.07.045.CrossRef

35.

Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharm. 2006;148:565–78. https://doi.org/10.1038/sj.bjp.0706780.CrossRef

36.

Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105:1276–82. https://doi.org/10.1111/j.1464-410X.2009.09036.x.CrossRefPubMed

37.

Kumar V, Templeman L, Chapple CR, Chess-Williams R. Recent developments in the management of detrusor overactivity. Curr Opin Urol. 2003;13:285–91. https://doi.org/10.1097/01.mou.0000079412.62186.66.CrossRefPubMed

38.

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;7:CD005493. https://doi.org/10.1002/14651858.CD005493.pub3.CrossRef

39.

Adile B, Speciale P, Gugliotta G, Consiglio P, Manzone M, Adile G, et al. Efficacy and acceptance of the sacral neuromodulation in the treatment of female lower urinary tract dysfunctions. Minerva Ginecol. 2018;70:236–8. https://doi.org/10.23736/S0026-4784.17.04135-1.CrossRefPubMed

40.

McGuire EJ, Fitzpatrick CC, WanJ BD, Sanvordenker J, Ritchey M, et al. Clinical assessment of urethral sphincter function. J Urol. 1993;150:1452–4. https://doi.org/10.1016/s0022-5347(17)35806-8.CrossRefPubMed

41.

Smith P. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring. Acta Obstet Gynecol Scand. 1993;157:1–25.

42.

Falconer C, Ekman-Ordeberg G, Ulmsten U, Westergren-Thorsson G, Barchan K, Malmstrom A. Changes in paraurethral connective tissue at menopause are counteracted by estrogen. Maturitas. 1996;24:197–204.CrossRef

Titel: Is Vaginal Laser Effective for Overactive Bladder? Results of a Systematic Review
verfasst von: Gloria Calagna
Marianna Maranto
Emanuela Ognibene
Salvatore Polito
Pasquale De Franciscis
Roberta Granese
Gaspare Cucinella
Publikationsdatum: 06.11.2019
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 4/2019
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-019-00535-6

Rectourethral Fistula—Review of Current Practices, Developments, and Outcomes

Cancer-Associated Voiding Dysfunction (S Elliott and J Pariser, Section Editor)

Combination Therapy for Bladder Dysfunction in Patients with Neurogenic Detrusor Overactivity

Neurogenic Bladder (C Powell, Section Editor)

Vesicourethral Anastomotic Stenosis after Prostate Cancer Treatment

Cancer-Associated Voiding Dysfunction (S Elliott and J Pariser, Section Editors)

Overactive Bladder in Diabetes Mellitus

Overactive Bladder (U Lee and S Adelstein, Section Editors)

Radiation Cystitis: a Contemporary Review

Cancer-Associated Voiding Dysfunction (S Elliott and J Pariser, Section Editors)

Post-Prostatectomy Incontinence: an Update on Current Management

Cancer-Associated Voiding Dysfunction (S Elliott and J Pariser, Section Editors)

Neu im Fachgebiet Urologie

Bei „Harnwegsinfekt“ mit Fieber an akute Prostatitis denken!

08.01.2025
Prostatitis
Nachrichten

Symptome eines Harnwegsinfekts sind bei geriatrischen Patienten keinesfalls auf die leichte Schulter zu nehmen. Der Urogeriater Prof. Andreas Wiedemann von der Uni Witten/Herdecke warnt vor zwei schweren Krankheitsbildern, die immer noch häufig übersehen werden, und gibt praktische Tipps für die Diagnostik.

Ab diesem Alter lohnt sich das PSA-Screening kaum noch

08.01.2025
PSA-Screening
Nachrichten

Die Gefahr, einen gefährlichen Prostatatumor zu haben oder zu entwickeln, ist vor allem bei PSA-Werten jenseits von 3 ng/ml erhöht. Doch auch Werte, die darunter liegen, können ein erhöhtes Risiko darstellen – vor allem im jungen Alter. Doch wie sieht es bei älteren Patienten aus?

Harnwegsinfekte: Was taugt die antibiotische Kurzzeittherapie bei Kindern?

07.01.2025
Harnwegsinfektionen in der Pädiatrie
Nachrichten

In einer aktuellen Metaanalyse wurde untersucht, wie erfolgsversprechend eine verkürzte Antibiotikatherapie bei afebrilen Kindern mit Harnwegsinfekten im Vergleich zur Standardtherapie ist. In gewissen Fällen könnte die Kurzzeittherapie ausreichen.

Harnwegsinfekte – vielfältige Verläufe, vielfältige Strategien

17.12.2024
Harnwegsinfektionen
Podcast

Das Spektrum an Harnwegsinfektionen reicht von der asymptomatischen Bakteriurie bis hin zur schweren Urosepsis. Was spricht für einen komplizierteren Verlauf? Wann sollte umgehend eine Ultraschall-Untersuchung erfolgen? Und welchen Wert haben Cranberrys, Antibiotika oder Impfungen bei der Rezidivprophylaxe? Prof. Sibylle von Vietinghoff klärt auf und ordnet die diagnostischen und therapeutischen Pfade.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Is Vaginal Laser Effective for Overactive Bladder? Results of a Systematic Review